Plain-English translation of NCT06840717 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand why some children develop type 2 asthma by comparing genes and immune markers in children with asthma versus healthy children. Type 2 asthma is a specific type that involves high levels of inflammation markers in the body. By studying genetic differences, scientists hope to learn what makes some children more likely to develop this form of asthma.
Type 2 asthma in children is driven by specific immune system patterns, but doctors don't fully understand which genetic differences make children more vulnerable. This study aims to identify genetic risk factors so doctors can better predict, diagnose, and eventually treat this type of asthma.
You likely qualify if…
You likely don't qualify if…
As a participant, you would visit the pediatric respiratory clinic where doctors will take blood or sputum samples and perform breathing tests to measure your lung function and inflammation markers. Researchers will compare your genetic information and immune markers with those of healthy children in the control group. The study involves no medication or treatment — only testing and sample collection to help scientists understand the genetic basis of type 2 asthma.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Sponsor
Guangzhou Institute of Respiratory Disease
Enrollment target
~300 participants
Started
January 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
3 Years – 14 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lihong Sun, M.D.
Guangzhou Institute of Respiratory Disease
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.